PTEN expression as a predictor of response to focal adhesion kinase inhibition in uterine cancer

Molecular Cancer Therapeutics

Volumn 14, Issue 6, 2015, Pages 1466-1475

  Thanapprapasr, Duangmani ^a,b   Previs, Rebecca A ^a   Hu, Wei ^a   Ivan, Cristina ^a   Armaiz Pena, Guillermo N ^a   Dorniak, Piotr L ^a   Hansen, Jean M ^a   Rupaimoole, Rajesha ^a   Huang, Jie ^a   Dalton, Heather J ^a   Ali Fehmi, Rouba ^c   Coleman, Robert L ^a   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD31 ANTIGEN; CISPLATIN; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; GSK 2256098; KI 67 ANTIGEN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TOPOTECAN; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; GSK2256098; HYDROXAMIC ACID; PTEN PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER SURVIVAL; CAPILLARY DENSITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERUS CANCER; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SCREENING; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PHOSPHORYLATION; PREDICTIVE VALUE; PROGNOSIS; TUMOR CELL LINE; UTERINE NEOPLASMS; VASCULARIZATION; WESTERN BLOTTING;

AMINOPYRIDINES; ANIMALS; ANTIGENS, CD31; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; HYDROXAMIC ACIDS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MICE, NUDE; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; UTERINE NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942081974     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-1077     Document Type: Article

References (45)

1. American Cancer Society. Cancer Facts & Figures 2010. Available from: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2010/index.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
3. Dizon DS. Treatment options for advanced endometrial carcinoma. Gynecol Oncol 2010;117:373-81.
4. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2000;2:249-56.
5. Siesser PM, Hanks SK. The signaling and biological implications of FAK overexpression in cancer. Clin Cancer Res 2006;12:3233-7.
6. Sood AK, Coffin JE, Schneider GB, Fletcher MS, De Young BR, Gruman LM, et al. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol 2004;165:1087-95.
7. Canel M, Serrels A, Miller D, Timpson P, Serrels B, Frame MC, et al. Quantitative in vivo imaging of the effects of inhibiting integrin signaling via Src and FAK on cancer cell movement: effects on E-cadherin dynamics. Cancer Res 2010;70:9413-22.
8. Samarnthai N, Hall K, Yeh IT. Molecular profiling of endometrial malignancies. Obstet Gynecol Int 2010;2010:162363.
9. Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005;65:10669-73.
10. Gabriel B, Hasenburg A, Waizenegger M, Orlowska-Volk M, Stickeler E, Zur Hausen A. Expression of focal adhesion kinase in patients with endometrial cancer: a clinicopathologic study. Int J Gynecol Cancer 2009;19:1221-5.
11. Kong D, Suzuki A, Zou TT, Sakurada A, Kemp LW, Wakatsuki S, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 1997;17:143-4.
12. Cancer Genome Atlas Research N Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73.
13. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997;57:4736-8.
14. Schwock J, Dhani N, Hedley DW. Targeting focal adhesion kinase signaling in tumor growth and metastasis. Expert Opin Ther Targets 2010;14:77-94.
15. Chu EC, Tarnawski AS. PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit 2004;10:RA235-41.
16. Shi M, Zhang H, Li M, Xue J, Fu Y, Yan L, et al. Normal endometrial stromal cells regulate survival and apoptosis signaling through PI3K/AKT/Survivin pathway in endometrial adenocarcinoma cells in vitro. Gynecol Oncol 2011;123:387-92.
17. Catasus L, D'Angelo E, Pons C, Espinosa I, Prat J. Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of highgrade endometrial carcinomas with different molecular alterations. Mod Pathol 2010;23:694-702.
18. Steinbakk A, Malpica A, Slewa A, Skaland I, Gudlaugsson E, Janssen EA, et al. Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma. Mod Pathol 2011;24:1262-71.
19. Schultze A, Fiedler W. Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase. Anticancer AgentsMedChem 2011;11:593-9.
20. Zhang J, He DH, Zajac-Kaye M, Hochwald SN. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Cell Cycle 2014;13:3143-9.
21. Huang J, Hu W, Bottsford-Miller J, Liu T, Han HD, Zand B, et al. Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib. Clin Cancer Res 2014;20:1846-55.
22. Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, et al. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther 2010;10:1306-14.
23. Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, et al. Notch3 Pathway Alterations in Ovarian Cancer. Cancer Res 2014;74:3282-93.
24. Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R, et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 2007;13:7487-95.
25. Wu SY, Yang XB, Gharpure KM, Hatakeyama H, Eqli M, McGuire MH, et al. 20-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun 2014;5:3459.
26. Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, et al. Tumour angiogenesis regulation by the miR-200 family. Nat Commun 2013;4:2427.
27. Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekederli I, Graybill WS, et al. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst 2011;103:1596-612.
28. Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 2011;1:170-85.
29. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 2001;14:672-6.
30. Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, et al. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 1999;59:1820-4.
31. Lee HS, Lee HK, Kim HS, Yang HK, Kim WH. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 2003;200:39-46.
32. Lee JI, Soria JC, Hassan KA, El-Naggar AK, Tang X, Liu DD, et al. Loss of PTEN expression as a prognostic marker for tongue cancer. Arch Otolaryngol Head Neck Surg 2001;127:1441-5.
33. Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer 2003;10:203-8.
34. Tachibana M, Shibakita M, Ohno S, Kinugasa S, Yoshimura H, Ueda S, et al. Expression and prognostic significance of PTEN product protein in patients with esophageal squamous cell carcinoma. Cancer 2002;94:1955-60.
35. McConechy MK, Ding J, Cheang MC, Wiegand KC, Senz J, Tone AA, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol 2012;228:20-30.
36. Byron SA, Gartside M, Powell MA, Wellens CL, Gao F, Mutch DG, et al. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PloS ONE 2012;7:e30801.
37. Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW. PIK3R1 (p85a) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res 2011;71:4061-7.
38. Kuhn E, Wu RC, Guan B, Wu G, Zhang J, Wang Y, et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genomewide analyses. J Natl Cancer Inst 2012;104:1503-13.
39. Le Gallo M, O'Hara AJ, Rudd ML, Urick ME, Hansen NF, O'Neil NJ, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet 2012;44:1310-5.
40. Leslie NR, Downes CP. PTEN function: how normal cells control it and tumour cells lose it. Biochem J 2004;382:1-11.
41. Han SY, Kato H, Kato S, Suzuki T, Shibata H, Ishii S, et al. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res 2000;60:3147-51.
42. McConechy MK, Ding J, Senz J, Yang W, Melnyk N, Tone AA, et al. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol 2014;27:128-34.
43. Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer 2014;14:598-610.
44. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 2007;67:10976-83.
45. Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot C, et al. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst 2013;105:1485-95.